Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older
- People who have been newly diagnosed with multiple myeloma and whose doctor has determined they are not suitable for a stem cell transplant, based on specific guidelines
- People whose blood test results meet certain minimum levels: white blood cell count of at least 1.0×10⁹/L, platelet count of at least 50×10⁹/L, kidneys working at least 30% of normal capacity, and liver values within an acceptable range (confirm specific numbers with trial site)
- People whose doctor has decided that the Isa-VRd treatment combination (isatuximab plus three other medicines) is the intended treatment plan, separate from the study itself
- People who have signed a consent form agreeing to take part (this can be signed by a legal representative if needed)
Who may not be able to join:
- People who are currently taking part in another clinical trial that involves a treatment or intervention
- People who are known to have had a severe allergic reaction to isatuximab or any of its ingredients
- People who have a serious blood infection at the time treatment would begin
- People with certain heart or blood pressure conditions that are not currently under control, including uncontrolled high blood pressure, irregular heartbeat, heart failure, or unstable chest pain
- People who have moderate to severe nerve damage or nerve pain (known as peripheral neuropathy at Grade 2 or higher)
- People with an active infection, a known HIV diagnosis, or active hepatitis B or hepatitis C
- People who are currently pregnant
- People whose doctor believes they would not be able to tolerate one or more of the medicines in the treatment combination
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Peng Liu, Fudan University
Phone: +86-021-64041990
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
≥CR rate after induction treatment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.